To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
RMA Enters Multi Year Agreement with GeneGo to Access MetaCore
GeneGo, Inc. has announced that Reproductive Medicine Associates (RMA) of New Jersey have licensed MetaCore to use for research and in their clinic.
Primarily, MetaCore will be used for analysis of gene expression data from individual human oocytes and blastomers.
It was important for RMA that MetaCore has comprehensive curated content in the area of reproduction and is capable of concurrent analysis of multiple patients' datasets.
"We are pleased to have acquired this excellent research tool from GeneGo. MetaCore will increase our ability to translate research discoveries into clinical applications that will improve the quality of life for patients with infertility," said Dr. Nathan Treff, Principle Investigator of Molecular Biology at RMA of New Jersey.
"We are very pleased to see our tools licensed by RMA," said Julie Bryant, Vice President of Business Development at GeneGo.
"MetaCore has been applied extensively in the area of reproductive medicine by several pharmaceutical companies and academic groups, but this is the first time it will be used by health care practitioners."
"This is very encouraging as our ultimate goal is to adapt systems data analysis technology to the needs of doctors and individual patients."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
